Innovative Technology Emulate's pioneering Organ-on-a-Chip platform offers high-precision, human-relevant data generation, making it a valuable partner for pharmaceutical and biotech companies seeking advanced in vitro models to accelerate drug discovery and reduce late-stage failures.

Recent Product Launches The recent launch of the AVA Emulation System and Chip-R1 Rigid Chip demonstrates Emulate's continuous innovation in scalable, biologically relevant models, providing opportunities to sell complementary products, consumables, and customized solutions to research laboratories interested in cutting-edge in vitro testing.

Strategic Funding With a substantial funding of over $352 million and a recent $82 million Series E round, Emulate is positioned for further expansion and technological development, opening opportunities to collaborate or supply specialized components, reagents, and support services for growing research demand.

Industry Recognition Being named to Fast Company’s list of the World’s Most Innovative Companies elevates Emulate's visibility and credibility, making it easier for business development teams to approach leading pharmaceutical and academic institutions with partnership and distribution proposals.

Expanding Customer Base Targeting top pharmaceutical and biotech firms already using Emulate’s platforms provides a prime opportunity to upsell new product lines, maintenance services, and tailored research tools, especially as demand for more predictive human-relevant models continues to grow.